All In Biotech

Drug Trial Radar · NCT06383052

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Apr 26, 2024

Primary completion

Jun 30, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Norroy Bioscience Co., LTDIndustry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • 177Lu-NYM032 injectionDrug

    Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Dose Limiting Toxicity (DLT)Time frame: 28 days
  2. Maximum Tolerated Dose (MTD)Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affliated Hospital of Jiangnan University

    Wuxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.